Organic compounds -- part of the class 532-570 series – Organic compounds – Sulfur containing
Reexamination Certificate
2003-05-23
2004-11-23
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Sulfur containing
C568S018000, C568S027000, C568S032000, C514S706000, C514S708000, C514S709000
Reexamination Certificate
active
06822120
ABSTRACT:
BACKGROUND
Liver X-receptors (LXRs) are nuclear receptors that regulate the metabolism of several important lipids, including cholesterol and bile acids. Most of the cholesterol in plasma is transported on three major lipoprotein classes; VLDL cholesterol (VLDL-C), LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C). Total cholesterol is the sum of all three lipoproteins. Both VLDL-C and LDL-C are associated with atherogenic processes while HDL-C is believed to facilitate cholesterol removal from tissues (e.g. atherosclerotic plaques) and thus have a protective effect on coronary heart disease.
LXR represents a novel intervention point to regulate the reverse cholesterol transport (RCT) pathway, i.e., the removal of cholesterol from peripheral tissues/cells and subsequent uptake via the liver for disposal. Removal of cellular cholesterol requires active transport of free cholesterol across the plasma membrane and onto HDL particles. This transfer of cholesterol from inside the cell and onto HDL in the plasma is mediated by ATP binding cassette 1 (ABCA1) transporter protein. The observation that LXR is a key transcriptional activator of ABCA1 in the macrophage, suggests that induction of LXR will lead to an increase in cholesterol efflux from the macrophage. In addition, it is known that LXR regulates the induction of other genes involved in RCT such as apoE and cholesterol ester transport protein (CETP), suggesting that activating the LXR pathway should also lead to increased uptake of cholesterol by the liver. Thus, activation of LXR by a small molecule ligand will lead to an up-regulation of ABCA1 and induction of the reverse cholesterol transport pathway thereby increasing cholesterol efflux to HDL-C and reducing the cholesterol content of atherosclerotic plaques.
SUMMARY OF THE INVENTION
In general, the present invention is directed to LXR modulators being small-molecule compounds corresponding to Formula (I) and the isomers, tautomers, salts and prodrugs thereof:
wherein:
R
1
and R
2
are independently hydrogen or optionally substituted alkyl, alkenyl, aryl, acyl, or alkaryl;
R
3
is optionally substituted alkyl or aryl;
each R
4
is independently hydrogen, alkyl, aryl, heteroaryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amido, alkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkylcarbonyl, alkylthiocarbonyl, arylthiocarbonyl, alkyl optionally substituted with one or more substituent selected from lower alkyl, halogen, hydroxyl, haloalkyl, cyano, nitro, carboxyl, amino, alkoxy and aryl, or aryl optionally substituted with one or more substituent selected from hydrogen, halogen, haloalkyl, hydroxy, lower alkyl, alkoxy, methylene dioxy, ethylenedioxy, cyano, nitro, alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, carboxyl derivatives, amino, aryl and heteroaryl; and
a is 0-4.
REFERENCES:
patent: 3637803 (1972-01-01), Tsung-Ying et al.
patent: 5011851 (1991-04-01), Meanwell
patent: 5639616 (1997-06-01), Liao et al.
patent: 5684204 (1997-11-01), Matthews
patent: 6316503 (2001-11-01), Li et al.
patent: RE37770 (2002-06-01), Elias et al.
patent: 2001/0018428 (2001-08-01), Zablocki et al.
patent: 2001/0020030 (2001-09-01), Stewart et al.
patent: 2002/0013334 (2002-01-01), Robl et al.
patent: 2002/0016364 (2002-02-01), Luchoomun et al.
patent: 2002/0037872 (2002-03-01), Palle et al.
patent: 2002/0045607 (2002-04-01), Beachy et al.
patent: 2002/0048572 (2002-04-01), Shan et al.
patent: 2002/0120137 (2002-08-01), Houze et al.
patent: 2002/0165394 (2002-11-01), Dumas et al.
patent: 0 135 894 (1985-04-01), None
patent: 0 558 062 (1993-09-01), None
patent: WO 91/00277 (1991-01-01), None
patent: WO 91/00281 (1991-01-01), None
patent: WO 96/19493 (1996-06-01), None
patent: WO 96/34851 (1996-11-01), None
patent: WO 99/19300 (1999-04-01), None
patent: WO 00/54759 (2000-09-01), None
patent: WO 00/55118 (2000-09-01), None
patent: WO 00/56710 (2000-09-01), None
patent: WO 01/60818 (2001-08-01), None
patent: WO 02/20463 (2002-03-01), None
patent: WO 02/24632 (2002-03-01), None
patent: WO 02/46141 (2002-06-01), None
patent: WO 02/46172 (2002-06-01), None
patent: WO 02/46181 (2002-06-01), None
CA:137:198704 abs of Molecular Endocrinology by Whitney et al 16(6) pp1378-1385 2002.*
CA:138:22685 abs of WO2003002118 Jan. 2003.*
CA:140:69940 abs of Arteriosclerosis, Thrombosisn and Vascular Biology by Lund et al 23(7) pp1169-1177 2003.*
CA:138:163703 abs of Diabetes by Stulnig et al 51(8) pp 2426-2433 2002.*
CA:139:359713 abs of Steroids by Fukuchi et al 68(7-8) pp 685-691 2003.*
CA:135:75010 abs of Steroids by Song et al 66(6) pp 473-9 2001.
Becker Daniel P.
Collins Joe T.
DeCrescenzo Gary A.
Malecha James W.
Miyashiro Julie M.
Kumar Shailendra
Pharmacia Corporation
LandOfFree
Sulfone liver X-receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfone liver X-receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfone liver X-receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3302606